Dewpoint: the leader in condensate biology that is breaking new ground in drug discovery

10 January 2024

Plenty of biotech companies claim to be leading a revolution with their approach to disease.

The difference with Dewpoint Therapeutics is that it is spearheading a revolutionary shift in drug discovery with its focus on the role of biomolecular condensates in disease pathogenesis. Leveraging ground-breaking new insights into cell biology, Dewpoint is decoding the intricate mechanisms of diseases to pioneer novel treatments.

“Dewpoint Therapeutics was founded on the ground-breaking realization that biomolecular condensates - dynamic, membraneless cellular structures that compartmentalize biological processes - are not only crucial to normal cellular functions, but are also implicated in disease manifestation, including cancer, neurodegeneration and cardio-metabolic disorders,” Dr Ameet Nathwani (pictured, inset image below), chief executive of Dewpoint shared with The Pharma Letter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK